血液透析机高通量透析与常规透析在治疗慢性肾衰竭尿毒症期患者的价值  

The Value of High-Throughput Hemodialysis and Routine Dialysis in Uremic Patients with Chronic Renal Failure

作　　者：黄姗姗 HUANG Shan-shan(Tianjin Peking University Medical Offshore Oil Hospital,Tianjin 300452)

机构地区：[1]天津北大医疗海洋石油医院,天津300452

出　　处：《中国医疗器械信息》2022年第22期144-146,共3页China Medical Device Information

摘　　要：目的:分析在慢性肾衰竭尿毒症期患者接受血液透析机治疗的过程中高通量透析与常规透析的临床应用效果与价值。方法:本研究对象为在本院接受血液透析机治疗的慢性肾衰竭尿毒症期患者56例,根据患者透析方式的不同实现分组,其中接受高通量透析的患者28例,将其作为研究组,接受常规透析的患者28例,将其作为参照组。结果:参照组患者治疗效果显著差于研究组患者,P<0.05。两组患者治疗前后小分子毒素清除情况差异并不显著,P>0.05;治疗前两组患者中、大分子毒素、免疫球蛋白水平差异无统计学意义,P>0.05,治疗后研究组患者上述指标显著差异于参照组患者,P<0.05。两组患者并发症发生率差异显著,P<0.05。结论:血液透析机高通量透析是慢性肾衰竭尿毒症期患者的理想治疗方式。Objective:To analyze the clinical effect and value of high throughput dialysis and routine dialysis in uremic stage of chronic renal failure.Methods:The subjects of this study were 56 uremic patients with chronic renal failure who received hemodialysis machine treatment in our hospital.According to the different implementation of dialysis methods,patients were divided into groups,including 28 patients receiving high-throughput dialysis as the study group,and 28 patients receiving routine dialysis as the reference group.Results:The treatment effect of the patients in the reference group was significantly worse than that of the patients in the study group(P<0.05).There was no significant difference in clearance of small molecule toxins between the two groups before and after treatment(P>0.05);There was no significant difference between the two groups in the levels of middle and macromolecular toxins and immunoglobulins before treatment(P>0.05);After treatment,the above indexes of patients in the study group were significantly different from those in the reference group(P<0.05).There was a significant difference in the incidence of complications between the two groups(P<0.05).Conclusion:High-throughput hemodialyzer is an ideal treatment for uremic patients with chronic renal failure.

关 键 词：血液透析机 高通量透析 常规透析 慢性肾衰竭 尿毒症期 

分 类 号：R459.5[医药卫生—治疗学]